Physician profile
Della Mathew
NPI 1629028428
$3,775.43
in general payments reported to CMS, 2019-2025
24 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.39 · 2020: $97.68 · 2021: $28.94 · 2022: $306 · 2023: $1,022 · 2024: $278 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,162 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.11 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $660.43 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $485.98 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $482.11 | 2022-2025 | Zepbound, Kisunla, Mounjaro |
| Astellas Pharma US INC | $412.78 | 2023-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $374.52 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $261.62 | 2022-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $176.11 | 2023 | |
| Viiv Healthcare Company | $149.20 | 2025 | Cabenuva |
| Novartis Pharmaceuticals Corporation | $127.85 | 2021-2024 | |
| Abiomed | $120.63 | 2025 | |
| Abbvie INC. | $103.14 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $80.20 | 2024-2025 | |
| Abbott Laboratories | $39.47 | 2024-2025 | Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $37.87 | 2025 | |
| Ucb, INC. | $37.52 | 2023 | Briviact, Nayzilam |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $35.93 | 2023 | Gemtesa |
| Exact Sciences Corporation | $31.75 | 2023-2025 | Cologuard Collection Kit |
| Si-Bone, INC. | $28.49 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.26 | 2024 | Xifaxan, Trulance |
| Inspire Medical Systems, INC. | $24.77 | 2024 | Inspire |
| Dexcom, INC. | $23.28 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $21.11 | 2025 | Rexulti |
| Cmp Pharma, INC. | $18.10 | 2022 | |
| Amarin Pharma, INC. | $15.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Della Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.